Bookmark
Forward
QuickView for Cefotetan (compound)
PubChem
| Name: | Cefotetan |
|---|---|
| PubChem Compound ID: | 4630412 |
| Description: | A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. |
| Molecular formula: | C17H17N7O8S4 |
| Molecular weight: | 575.623 g/mol |
DrugBank
Identification
| Name: | Cefotetan |
|---|---|
| Name (isomeric): | DB01330 |
| Drug Type: | small molecule |
| Description: | A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. |
| Synonyms: |
Cefotetanum [inn-latin]
|
| Brand: | Cefotan, Yamatetan |
| Category: | Cephalosporins, Anti-Bacterial Agents |
| CAS number: | 69712-56-7 |
Pharmacology
| Indication: | For prophylaxis and treatment of bacterial infections. |
|---|---|
| Pharmacology: | Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. |
| Mechanism of Action: | The bactericidal action of cefotetan results from inhibition of cell wall synthesis by binding and inhibiting the bacterial penicillin binding proteins which help in the cell wall biosynthesis. |
| Protein binding: | Cefotetan is 88% plasma protein bound. |
| Biotransformation: | No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. |
| Route of elimination: | No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations. |
| Half Life: | In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged |
| Clearance: | 1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)] 1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)] |
| Affected organisms: | Enteric bacteria and other eubacteria |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Carriers
